CA
DSGN icon

CoreCap Advisors’s Design Therapeutics DSGN Stock Holding History

CoreCap Advisors’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,879
Closed -$11.1K – 2901
2025
Q1 		$11.1K Buy
2,879
+2,167
+304% +$10.3K ﹤0.01% 1775
2024
Q4 		$4.39K Buy
+712
New +$4.12K ﹤0.01% 2003

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

CoreCap Advisors's DSGN Position: Q2 2025 in Review

CoreCap Advisors sold out of Design Therapeutics (DSGN) in Q2 2025, closing a stake of 2,879 shares — an estimated $11.1K sold.

CoreCap Advisors first reported a position in DSGN in Q4 2024 and held it in 2 quarters. The position peaked at $11.1K in Q1 2025. 92 funds tracked by Wall St. Rank hold DSGN as of Q2 2025.

  • CoreCap Advisors reported no remaining Design Therapeutics position as of Q2 2025 after selling out during the quarter.
  • CoreCap Advisors sold 2,879 Design Therapeutics shares in Q2 2025, an estimated $11.1K.
  • CoreCap Advisors first reported a position in Design Therapeutics in Q4 2024 and held it in 2 quarters.
  • CoreCap Advisors's Design Therapeutics position peaked at $11.1K in Q1 2025.
  • 92 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2025.

Based on CoreCap Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.